JP2019516754A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516754A5
JP2019516754A5 JP2018561512A JP2018561512A JP2019516754A5 JP 2019516754 A5 JP2019516754 A5 JP 2019516754A5 JP 2018561512 A JP2018561512 A JP 2018561512A JP 2018561512 A JP2018561512 A JP 2018561512A JP 2019516754 A5 JP2019516754 A5 JP 2019516754A5
Authority
JP
Japan
Prior art keywords
cancer
cells
population
pluripotent cells
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516754A (ja
JP7563872B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/062604 external-priority patent/WO2017202949A1/en
Publication of JP2019516754A publication Critical patent/JP2019516754A/ja
Publication of JP2019516754A5 publication Critical patent/JP2019516754A5/ja
Priority to JP2022110028A priority Critical patent/JP7622006B2/ja
Priority to JP2024168499A priority patent/JP2025000812A/ja
Application granted granted Critical
Publication of JP7563872B2 publication Critical patent/JP7563872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561512A 2016-05-25 2017-05-24 癌を処置するための方法及び組成物 Active JP7563872B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022110028A JP7622006B2 (ja) 2016-05-25 2022-07-07 癌を処置するための方法及び組成物
JP2024168499A JP2025000812A (ja) 2016-05-25 2024-09-27 癌を処置するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305607 2016-05-25
EP16305607.0 2016-05-25
PCT/EP2017/062604 WO2017202949A1 (en) 2016-05-25 2017-05-24 Methods and compositions for treating cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022110028A Division JP7622006B2 (ja) 2016-05-25 2022-07-07 癌を処置するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2019516754A JP2019516754A (ja) 2019-06-20
JP2019516754A5 true JP2019516754A5 (enExample) 2020-07-09
JP7563872B2 JP7563872B2 (ja) 2024-10-08

Family

ID=56131478

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018561512A Active JP7563872B2 (ja) 2016-05-25 2017-05-24 癌を処置するための方法及び組成物
JP2022110028A Active JP7622006B2 (ja) 2016-05-25 2022-07-07 癌を処置するための方法及び組成物
JP2024168499A Pending JP2025000812A (ja) 2016-05-25 2024-09-27 癌を処置するための方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022110028A Active JP7622006B2 (ja) 2016-05-25 2022-07-07 癌を処置するための方法及び組成物
JP2024168499A Pending JP2025000812A (ja) 2016-05-25 2024-09-27 癌を処置するための方法及び組成物

Country Status (11)

Country Link
US (2) US11458194B2 (enExample)
EP (1) EP3463433A1 (enExample)
JP (3) JP7563872B2 (enExample)
KR (3) KR20190032295A (enExample)
CN (2) CN109689089A (enExample)
AU (2) AU2017270234B2 (enExample)
BR (1) BR112018074192A8 (enExample)
CA (1) CA3025057A1 (enExample)
IL (2) IL263224B2 (enExample)
RU (1) RU2741786C2 (enExample)
WO (1) WO2017202949A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP7373991B2 (ja) 2016-07-15 2023-11-06 ビラクタ セラピューティクス，インク． 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
AU2018371212B2 (en) * 2017-11-24 2025-04-17 Assistance Publique - Hôpitaux De Paris Methods and compositions for treating cancers
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
US11298380B2 (en) 2018-01-02 2022-04-12 Khloris Biosciences, Inc. IPSC-based vaccine as a prophylactic and therapeutic treatment for cancer
EP3737405A4 (en) * 2018-01-12 2021-10-06 Viracta Therapeutics, Inc. EPIGENETIC MODIFIERS FOR USE IN CELLULAR IMMUNOTHERAPY
CN112703011A (zh) * 2018-08-06 2021-04-23 国家医疗保健研究所 用于治疗癌症的方法和组合物
US20220154219A1 (en) * 2019-03-22 2022-05-19 The Johns Hopkins University Gene delivery particles to induce tumor-derived antigen presenting cells
CN114144231B (zh) * 2019-05-15 2024-05-24 得克萨斯系统大学评议会 用于治疗癌症的crispr方法
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
GB202006254D0 (en) * 2020-04-28 2020-06-10 Institute Of Cancer Res Anti-cancer vaccines and related therapy
US20230174636A1 (en) * 2020-05-12 2023-06-08 Rush University Medical Center Compositions and methods for treating cancer
CN112603995B (zh) * 2020-12-30 2022-03-18 四川省肿瘤医院 靶向CAFs的肿瘤细胞疫苗、其制备方法及其应用
MX2023009699A (es) * 2021-03-31 2023-08-28 Celleron Therapeutics Ltd Adyuvante de vacuna.
US20250281510A1 (en) * 2021-04-05 2025-09-11 Pinotbio, Inc. Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax
US20250146080A1 (en) * 2022-02-17 2025-05-08 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
CN115494237B (zh) * 2022-09-19 2025-06-24 浙江省人民医院 Rps6ka2在制备卵巢癌诊断试剂和治疗药物中的应用
WO2024178965A1 (en) * 2023-02-27 2024-09-06 Wuhan University Modulation of pd-1 signaling for treatment of diseases

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4806476A (en) 1983-09-08 1989-02-21 Lovelace Medical Foundation Efficient cell fusion process
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
DE68928914T2 (de) 1988-08-04 1999-09-09 Amrad Corp. Ltd. (in vitro)-vermehrung von embryonalen stammzellen unter verwendung von leukämie-inhibitionsfaktor (lif)
US5240840A (en) 1991-04-05 1993-08-31 Regents Of The University Of Michigan Dna superfragment cloning
JP3314241B2 (ja) 1992-04-06 2002-08-12 ヤマハ発動機株式会社 自動二輪車用エンジンの排気浄化装置
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
WO1995002420A2 (en) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
JP3880795B2 (ja) 1997-10-23 2007-02-14 ジェロン・コーポレーション フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法
US6835867B1 (en) 1998-06-24 2004-12-28 Richard P. Woychik Allelic series of genomic modifications in cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001000207A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
BR0013899A (pt) 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
KR100681724B1 (ko) 1999-10-19 2007-02-28 머크 앤드 캄파니 인코포레이티드 티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물
JP2003512353A (ja) 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
NL1017973C2 (nl) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
US6921632B2 (en) 2000-08-30 2005-07-26 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
EP2354227B1 (en) 2001-05-31 2017-04-19 Shinya Yamanaka Genes with ES cell-specific expression
AU2002346053B2 (en) 2001-06-22 2008-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7592177B2 (en) 2003-11-10 2009-09-22 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
CN101490244A (zh) 2006-07-20 2009-07-22 理查德·伯特 利用有丝分裂灭活的干细胞修复损伤组织的方法
EP2091525A1 (en) 2006-12-06 2009-08-26 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN101855350B (zh) 2008-05-02 2014-12-31 国立大学法人京都大学 核重编程序方法
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2635678A4 (en) 2010-11-04 2014-04-23 Univ Kyoto METHOD FOR EFFICIENT MANUFACTURE OF INDUCED PLURIPOTENTER STEM CELLS
US9534206B2 (en) * 2010-12-16 2017-01-03 General Electric Company Cell carrier, associated methods for making cell carrier and culturing cells using the same
US20130136722A1 (en) * 2011-11-11 2013-05-30 The Board Of Trustees Of The University Of Illinois Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Similar Documents

Publication Publication Date Title
RU2018141200A (ru) Способы и композиции для лечения опухолей
JP2021504465A5 (enExample)
Mazzone et al. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
JP5452231B2 (ja) 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン
Vandenberk et al. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines
JP2022093564A (ja) キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法
Schnekenburger et al. Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments
Zhong et al. Immunotherapy for hepatocellular carcinoma: current limits and prospects
CN117731763A (zh) 过继细胞转移与溶瘤病毒组合疗法
RU2021132734A (ru) Химерные рецепторы антигена, нацеленные на psca
Du et al. Hypothermic microenvironment plays a key role in tumor immune subversion
JP2013537187A5 (enExample)
JP2012515213A5 (enExample)
JP2018506995A5 (enExample)
JP2021519087A5 (enExample)
JP2019512020A5 (enExample)
JP2018048151A5 (enExample)
WO2016020434A1 (en) Method for expanding immune cells
CN105873639A (zh) 自体肿瘤疫苗和方法
CA3200513A1 (en) Tumor cell vaccines
Obertopp et al. Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes
Nejad et al. Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
JP2020535832A5 (enExample)
Har-Noy et al. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma
Teitz-Tennenbaum et al. Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model